全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Cross Neutralization of Afro-Asian Cobra and Asian Krait Venoms by a Thai Polyvalent Snake Antivenom (Neuro Polyvalent Snake Antivenom)

DOI: 10.1371/journal.pntd.0001672

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Snake envenomation is a serious public health threat in the rural areas of Asian and African countries. To date, the only proven treatment for snake envenomation is antivenom therapy. Cross-neutralization of heterologous venoms by antivenom raised against venoms of closely related species has been reported. The present study examined the cross neutralizing potential of a newly developed polyvalent antivenom, termed Neuro Polyvalent Snake Antivenom (NPAV). NPAV was produced by immunization against 4 Thai elapid venoms. Principal Findings In vitro neutralization study using mice showed that NPAV was able to neutralize effectively the lethality of venoms of most common Asiatic cobras (Naja spp.), Ophiophagus hannah and kraits (Bungarus spp.) from Southeast Asia, but only moderately to weakly effective against venoms of Naja from India subcontinent and Africa. Studies with several venoms showed that the in vivo neutralization potency of the NPAV was comparable to the in vitro neutralization potency. NPAV could also fully protect against N. sputatrix venom-induced cardio-respiratory depressant and neuromuscular blocking effects in anesthetized rats, demonstrating that the NPAV could neutralize most of the major lethal toxins in the Naja venom. Conclusions/Significance The newly developed polyvalent antivenom NPAV may find potential application in the treatment of elapid bites in Southeast Asia, especially Malaysia, a neighboring nation of Thailand. Nevertheless, the applicability of NPAV in the treatment of cobra and krait envenomations in Southeast Asian victims needs to be confirmed by clinical trials. The cross-neutralization results may contribute to the design of broad-spectrum polyvalent antivenom.

References

[1]  Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, et al. (2008) The global burden of snakebite: A literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 5: e218. doi: 10.1371/journal.pmed.0050218
[2]  WHO (2010) Guidelines for the prevention and clinical management of snakebite in Africa. Brazzaville: WHO Regional Office for Africa.
[3]  Warrell DA (1995) Clinical toxicology of snakebite in Asia. In: Meier J, White J, editors. Handbook of clinical toxicology of animal venoms and poisons. Florida: CRC Press. pp. 493–594.
[4]  O'shea M (2005) Venomous Snakes of the World. New Jersey: Princeton University Press.
[5]  Chippaux JP (2006) Snake venoms and envenomations. Florida: Krieger Publishing Company.
[6]  Warrell DA (2010) Guidelines for the management of snake-bite. 87 p. WHO.
[7]  Williams D (2011) Global Snake Bite Initiative News. 59 p. International Society on Toxinology Newsletter.
[8]  Howard-Jones N (1985) A CIOMS ethical code for animal experimentation. WHO Chron 39: 51–56. doi: 10.1163/156853807780202495
[9]  Bradford MM (1976) Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254. doi: 10.1016/0003-2697(76)90527-3
[10]  Studier FW (1973) Analysis of bacteriophage T7 early RNAs and proteins on slab gels. J Mol Biol 79: 237–248. doi: 10.1016/0022-2836(73)90003-X
[11]  Ramos-Cerrillo B, de Roodt AR, Chippaux J-P, Olguín L, Casasola A, et al. (2008) Characterization of a new polyvalent antivenom (Antivipmyn? Africa) against African vipers and elapids. Toxicon 52: 881–888. doi: 10.1016/j.toxicon.2008.09.002
[12]  Morais V, Ifran S, Berasain P, Massaldi H (2010) Antivenoms: potency or median effective dose, which to use? Journal of Venomous Animals and Toxins including Tropical Diseases 16: 191–193. doi: 10.1590/s1678-91992010000200002
[13]  Finney D (1952) Probit Analysis. Cambridge: Cambridge University Press.
[14]  Chippaux JP (2010) Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Biol Aujourdhui 204: 87–91. doi: 10.1051/jbio/2009043
[15]  Raweerith R, Ratanabanangkoon K (2005) Immunochemical and biochemical comparisons of equine monovalent and polyvalent snake antivenoms. Toxicon 45: 369–375. doi: 10.1016/j.toxicon.2004.10.019
[16]  Wüster W, Thorpe RS (1991) Asiatic cobras: systematics and snakebite. Experientia 47: 205–209. doi: 10.1007/BF01945429
[17]  Minton SA Jr (1967) Paraspecific protection by elapid and sea snake antivenins. Toxicon 5: 47–55. doi: 10.1016/0041-0101(67)90118-3
[18]  Wüster W, Crookes S, Ineich I, Mané Y, Pook CE, et al. (2007) The phylogeny of cobras inferred from mitochondrial DNA sequences: Evolution of venom spitting and the phylogeography of the African spitting cobras (Serpentes: Elapidae: Naja nigricollis complex). Molecular Phylogenetics and Evolution 45: 437–453. doi: 10.1016/j.ympev.2007.07.021
[19]  Tan NH, Armugam A (1990) In vivo interactions between neurotoxin, cardiotoxin and phospholipases A2 isolated from Malayan cobra (Naja naja sputatrix) venom. Toxicon 28: 1193–1198. doi: 10.1016/0041-0101(90)90119-R
[20]  Warrell DA, Warrell MJ, Edgar W, Prentice CR, Mathison J (1980) Comparison of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper (Echis carinatus). Br Med J 280: 607–609. doi: 10.1136/bmj.280.6214.607

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133